Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy and safety of esmirtazapine in adult insomnia: unsupported statements about residual daytime effects.

Literature DB >> 33100265

Efficacy and safety of esmirtazapine in adult insomnia: unsupported statements about residual daytime effects.

R Bart Sangal¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33100265 PMCID： PMC7853227 DOI： 10.5664/jcsm.8912

Source DB: PubMed Journal: J Clin Sleep Med ISSN： 1550-9389 Impact factor: 4.062

× No keyword cloud information.

8 in total

1. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

Authors: Neely Ivgy-May; Goeran Hajak; Gonnie van Osta; Sabine Braat; Qing Chang; Thomas Roth
Journal: J Clin Sleep Med Date: 2020-09-15 Impact factor: 4.062

2. Baseline Lighter Sleep and Lower Saturation Are Associated With Improved Sleepiness and Adherence on Continuous Rather Than Autotitrating Positive Airway Pressure.

Authors: R Bart Sangal; Nimish Sudan
Journal: Clin EEG Neurosci Date: 2019-12-18 Impact factor: 1.843

3. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Authors: W Joseph Herring; Kathryn M Connor; Neely Ivgy-May; Ellen Snyder; Ken Liu; Duane B Snavely; Andrew D Krystal; James K Walsh; Ruth M Benca; Russell Rosenberg; R Bart Sangal; Kerry Budd; Jill Hutzelmann; Heather Leibensperger; Samar Froman; Christopher Lines; Thomas Roth; David Michelson
Journal: Biol Psychiatry Date: 2014-10-23 Impact factor: 13.382

8. Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study.

Authors: Naohisa Uchimura; Atsushi Kamijo; Takao Takase
Journal: Ann Gen Psychiatry Date: 2012-06-25 Impact factor: 3.455

8 in total

1 in total

1. Residual daytime effects of esmirtazapine.

Authors: Neely Ivgy-May
Journal: J Clin Sleep Med Date: 2021-04-01 Impact factor: 4.062

1 in total

Efficacy and safety of esmirtazapine in adult insomnia: unsupported statements about residual daytime effects.

1. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

2. Baseline Lighter Sleep and Lower Saturation Are Associated With Improved Sleepiness and Adherence on Continuous Rather Than Autotitrating Positive Airway Pressure.

3. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Review 4. Clinical pharmacokinetics of mirtazapine.

5. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.

Review 6. Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division).

7. Trazodone increases arousal threshold in obstructive sleep apnoea.

8. Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study.

1. Residual daytime effects of esmirtazapine.